Polyp Biopsy Market
Report ID: SQMIG35D2577
Report ID: SQMIG35D2577
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35D2577 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
117
|Figures:
77
Global Polyp Biopsy Market size was valued at USD 25.9 Billion in 2024 and is poised to grow from USD 27.92 Billion in 2025 to USD 60.92 Billion by 2033, growing at a CAGR of 7.81% during the forecast period (2026-2033).
The global polyp biopsy market comprises devices and services that enable the extraction and pathological analysis of gastrointestinal polyps, a critical step in early cancer detection. The significance of the topic lies in the increasing occurrence of colorectal cancer and the growing screening initiatives across North America, Europe, and Asia. The market was traditionally characterized by cold forceps and snares, but the start of access to the endoscopic submucosal dissection kit has made the market advance significantly more quickly due to the evidence that more tissue sampling leads to a decrease in missed lesions that encouraged hospitals to enhance their endoscopy suites.
One key trend driving the global polyp biopsy sector expansion is the integration of artificial intelligence into endoscopic imaging, which improves polyp detection rates and informs targeted biopsy decisions. When AI algorithms flag suspicious lesions in real time, clinicians can perform immediate, image‑guided sampling, thereby shortening procedure time and increasing diagnostic yield. This capability has been adopted by leading hospital networks in Japan, where AI‑assisted colonoscopy reduced missed adenomas by 30 percent, prompting procurement of compatible biopsy devices. The achievement of operational efficiency creates a cycle of responsiveness: the increased accuracy enhances the confidence of insurance companies, leading to larger reimbursement coverage.
How is AI Improving Accuracy in the Polyp Biopsy Market?
By advancing gastrointestinal endoscopy accuracy and efficiency, artificial intelligence is reshaping the global polyp biopsy market. CADe systems utilize AI technology to scrutinize images obtained through endoscopies, thereby helping in detecting flat polyps or any other type which may require biopsies. By raising the adenomas detection rate, artificial intelligence promotes effective and early biopsy decision-making while reducing unnecessary tissues sampling. As more healthcare personnel use AI-assisted endoscopy to improve colorectal cancer screening, the demand for advanced biopsy equipment and accessories rises. In May 2025, Olympus Corporation introduced its OLYSENSE™ Platform that features the CADDIE™ AI detection system, thus supporting transition towards application of AI in medical practice.
In May 2025, Olympus Corporation: Olympus demonstrated its OLYSENSE™ Platform integrated with the CADDIE™ AI-powered detection system at Digestive Disease Week (DDW) 2025. The solution provides real-time identification of colorectal polyps during colonoscopy, helping physicians improve biopsy accuracy, increase adenoma detection rates, and support earlier diagnosis of gastrointestinal cancers through AI-assisted endoscopy.
Market snapshot - (2026-2033)
Global Market Size
USD 25.9 Billion
Largest Segment
Instruments
Fastest Growth
Kits and Consumables
Growth Rate
7.81% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global polyp biopsy market is segmented by product, type, application, end user and region. Based on product, the market is segmented into instruments, kits and consumables and services. Based on type, the market is segmented into forceps biopsy, snare biopsy and brush biopsy. Based on application, the market is segmented into colorectal polyps, gastric polyps and nasal polyps. Based on end user, the market is segmented into hospitals, ambulatory surgical centers and diagnostic laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Based on the global polyp biopsy market growth, instruments segment dominates because clinicians prioritize precision tools that ensure complete tissue retrieval and minimize procedural complications. The use of tactile feedback, ergonomic designs and linking to imaging systems leads to assurance even in demanding situations aiding in the making of buying decisions in medical practice. This confidence boosts the utilization of the products resulting in their becoming essential elements in biopsy processes and securing the leadership position in the market. In addition, the manufacturers put a lot of effort into development of material science and components making the product more flexible for lesions of different sizes and anatomical regions. Continuous innovation also helps to keep doctors' confidence in those products allowing justifying the price of the products even when they have very high costs.
However, kits and consumables segment is witnessing the strongest growth momentum as personalized testing protocols drive demand for ready‑to‑use reagent packs and disposable biopsy accessories. The convenience of integrated kits reduces preparation time, supports sterile workflows, and aligns with value‑based purchasing, accelerating market expansion and opening new avenues for bundled service offerings.
Snare biopsy segment leads because its loop mechanism enables en bloc removal of larger mucosal lesions, delivering superior histopathological specimens. This ability corresponds with clinical recommendations that stress the significance of complete excision in accurate evaluation and eliminates the requirement for re-doing the operation. Therefore, endoscopists choose to use snare equipment in colorectal and gastric polyp surgeries, thus strengthening the boom of procurement cycle and maintaining the tool’s popularity in the polyp biopsy market. The efficiency of the procedure itself and the small incidence of complications trigger its popularity both in hospitals and outpatient clinics, making it a strong competitor in the market.
On the other hand, brush biopsy segment emerges as the most rapidly expanding area as minimally invasive sampling gains traction for nasal and early gastric lesions. Its flexible bristles facilitate access to hard‑to‑reach surfaces, offering clinicians a less traumatic alternative and encouraging broader screening programs. This growth fuels new device development and creates fresh revenue streams, propelling overall market dynamism.
To get detailed segments analysis, Request a Free Sample Report
As per the global polyp biopsy market share, North America leverages a mature healthcare ecosystem that combines extensive endoscopic expertise with comprehensive insurance coverage, enabling widespread adoption of advanced biopsy techniques. Good teamwork among academic centers, clinical labs and innovators of medical devices enables ongoing progress in performing procedures correctly and ensuring patients' safety. The strong regulatory regimes guarantee fast approval of new technologies while the preventive care culture stimulates extensive application of screening programs. All this creates favorable conditions for continued market leadership and further innovations in polyp biopsy.
Polyp biopsy market in United States thrives on a sophisticated network of tertiary care centers and a proactive patient population that embraces early detection. Combining modern imaging devices with accurate sampling procedures provides greater certainty in diagnosis. Continuous studies undertaken by renowned organizations support the clinical practice recommendations and strong support from the medical insurers means that advanced treatment is not expensive. The combination of these factors speeds up the introduction of new biopsy methods in medicine.
Polyp biopsy market in Canada benefits from a publicly funded system that prioritizes equitable access to preventive diagnostics. Policies at the national level have advanced general colonoscopy practices, increasing the need for credible biopsy technologies. Cooperation between provincial health departments and technology vendors allows timely implementation of procedures based on proven technologies. The focus on patient safety and efficiency of various procedures helps to develop standards for the industry.
Based on global polyp biopsy regional forecast, Europe’s growth is propelled by harmonized regulatory pathways that streamline product introductions across multiple jurisdictions, encouraging manufacturers to invest in the region. Strong public health policies endorse population‑wide screening, generating consistent volume for biopsy services. Academic centers produce cutting-edge research and technology, promoting the use of advanced methods and international collaborations. Payment methods that reward effective results stimulate the utilization of new machinery, and programs aimed at raising the public's knowledge about effective diagnostics increase the market potentials of new technologies.
Polyp biopsy market in Germany is anchored by a dense concentration of specialized gastroenterology clinics and a tradition of rigorous clinical standards. The country’s emphasis on evidence‑based practice drives continuous refinement of sampling protocols. Research institutions collaborating with companies is speeding up the process of bringing high-precision devices. Extensive insurance policies enhance accessibility, making it easier to use the most advanced ways of conducting a biopsy.
Polyp biopsy market in United Kingdom experiences rapid uptake driven by national screening programs that prioritize early detection of colorectal lesions. The merging of real-time imaging with targeted biopsy increases the efficiency of the procedures. Cooperative networks that connect NHS trusts to academic researchers ensure the quick transfer of innovations to practical care. The policies that promote the improvement of outcomes work in favor of the implementation of new technologies for biopsy in the health care system.
Polyp biopsy market in France is emerging as a dynamic segment supported by evolving clinical guidelines that emphasize minimally invasive diagnosis. Government-supported programs promote the application of advanced biopsy equipment across public healthcare facilities. Close cooperation between French research institutions and biotech companies boosts the innovation of new sampling techniques. Reimbursement policies that align with patient‑centered care models stimulate incremental growth in market activity.
As per global polyp biopsy regional outlook, Asia Pacific region is advancing through heightened awareness of gastrointestinal health and expanding middle‑class populations seeking preventive care. Government health policies are mainly focused on preventive measures and thus, there are investments made to enhance endoscopy facilities and carry out training programs in this field. Local manufacturers are now developing their own equipment for biopsy to compete with foreign manufacturers while foreign partnerships are enhancing the process of technology transfer. With increasing number of available clinical trials and implementation of international standards for procedures, the region gets established as a serious participant in the global landscape of polyp biopsy.
Polyp biopsy market in Japan benefits from a longstanding culture of meticulous clinical care and a highly organized screening infrastructure. Precise sampling tools combined with high-resolution imaging improve the yield of diagnostics. The good relationship between institutions of higher education and manufacturers of the equipment creates the ground for quick introduction of the new biopsy technology. The reimbursement policies that favor accuracy and patient outcome assist in further investments in these technologies.
Polyp biopsy market in South Korea is propelled by aggressive adoption of cutting‑edge endoscopic platforms and a proactive regulatory environment that encourages swift market entry. Government-driven health programs concentrate on early diagnosis, making it crucial to have dependable biopsy techniques. Joint research initiatives of hospitals and technology companies allow for continuous improvement in sampling methods, whereas the medical insurance systems offer full compensation for modern diagnostic technologies.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Advances and Integration Of AI
Growing Use Of Endoscopic Imaging
Regulatory Approval Delays
High Cost Of Specialized Equipment
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape in the global polyp biopsy market outlook is shaped by a handful of dominant players such as Angiotech, Cardinal Health, Carefusion Corporation, Cigna and C.R. Bard, each leveraging strategic M&A, joint development agreements and rapid technology roll‑outs to secure market share; recent partnership activity and acquisitions of niche biopsy device firms have intensified product differentiation and accelerated entry of advanced polyp biopsy solutions.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global polyp biopsy industry is driven primarily by AI integration that boosts real‑time detection and supports more comprehensive sampling, while expanding use of high‑definition endoscopic imaging serves as a second catalyst by revealing subtle lesions and prompting precise biopsies. Regulatory approval delays act as a restraint, extending time‑to‑market and raising development costs. North America remains the dominating region thanks to its mature healthcare infrastructure, strong reimbursement, and early adoption of advanced technologies. Within the market, the instruments segment leads, reflecting clinicians’ preference for precise, ergonomic tools that ensure complete tissue capture.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 25.9 Billion |
| Market size value in 2033 | USD 60.92 Billion |
| Growth Rate | 7.81% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Polyp Biopsy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Polyp Biopsy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Polyp Biopsy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Polyp Biopsy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Polyp Biopsy Market size was valued at USD 25.9 Billion in 2024 and is poised to grow from USD 27.92 Billion in 2025 to USD 60.92 Billion by 2033, growing at a CAGR of 7.81% during the forecast period (2026-2033).
The competitive landscape is shaped by a handful of dominant players such as Angiotech, Cardinal Health, Carefusion Corporation, Cigna and C.R. Bard, each leveraging strategic M&A, joint development agreements and rapid technology roll‑outs to secure market share; recent partnership activity and acquisitions of niche biopsy device firms have intensified product differentiation and accelerated entry of advanced polyp biopsy solutions. 'STAAR Surgical Company', 'Olympus Corporation', 'Cook Medical LLC', 'Inari Medical Inc', 'Steris plc', 'ConMed Corporation', 'Microtech Endoscopy USA Inc', 'US Endoscopy Group Inc', 'Fujifilm Holdings Corporation', 'Shockwave Medical Inc', 'Karl Storz SE and Co', 'Erbe Elektromedizin GmbH', 'Establishment Labs Holdings Inc', 'Merit Medical Systems Inc', 'Cutera Inc', 'Teleflex Incorporated', 'B Braun Melsungen AG', 'CC Diagnostics Pvt Ltd', 'Apollo Endosurgery Inc', 'Wilson Cook Medical Inc'
The integration of artificial intelligence into endoscopic systems enhances real‑time polyp detection accuracy and streamlines biopsy decision‑making, encouraging clinicians to adopt more comprehensive sampling protocols. This technological improvement reduces procedural uncertainty, shortens learning curves for new users, and supports confidence in obtaining diagnostically relevant tissue. As a result, hospitals and outpatient centers are motivated to invest in AI‑enabled platforms, driving demand for associated biopsy devices and consumables across diverse healthcare settings. The perceived clinical benefits also foster broader acceptance among multidisciplinary teams, further expanding market penetration.
Minimally Invasive Technology Adoption: The shift toward minimally invasive endoscopic platforms is driving demand for polyp biopsy tools that integrate seamlessly with advanced imaging modalities. Clinicians value devices that enable rapid tissue acquisition without compromising patient comfort, prompting manufacturers to redesign forceps and snares for smaller diameters and enhanced maneuverability. This evolution supports outpatient procedures, reduces hospital stays, and aligns with broader healthcare goals of cost efficiency and higher procedural throughput, positioning the market for sustained growth across emerging regional healthcare networks and institutions.
Why does North America Dominate the Global Polyp Biopsy Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
